torii pharmaceutical annual report

CONTENTS (68KB) Corporate Mission / The Torii Action Declaration (148KB) Message from the President / Progress of the "Medium … Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) "Financial Results " was updated. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. ... specifically our most recent Annual Report on … - Entered into an Option Agreement with Torii Pharmaceutical for the development and commercialization of VP-102 in Japan - WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- … JT concentrates on R&D, while Torii Pharmaceutical Co., Ltd. is in charge of manufacturing, sales, and promotion in the Japanese domestic market. Follow BCRX. Annual Report 2019. Torii is a member of Japan Tobacco Inc. (JT) group. The increase was primarily attributable to increased CMC costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum. BioCryst will receive a $22 million upfront payment and is eligible to receive up to an additional $20 million upon achievement of certain … Our Pharmaceutical investments in research and development continued to fuel exceptional growth as well. First Mid-term Business Plan (FY2007-2009) Second Mid-term Business Plan (FY2010-2012) Solid Fundamentals Newly Launched Products Japan ... concluded with Torii Pharmaceutical. Research and development expenses were $5.0 million in the third quarter of 2020, compared to $3.0 million for the same period in 2019. TORII PHARMACEUTICAL CO., LTD. produces and sells pharmaceuticals. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. “We have also received feedback from the FDA on our Human Factors study protocol, and believe we have clear alignment on the path forward to resubmit the NDA, which we anticipate in the first quarter of 2021. PDF(3.45MB). – Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 –. WEST CHESTER, PA – Nov. 9, 2020 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2020. The Company is also developing VP-103, its third cantharidin-based product candidate, for the treatment of plantar warts. August 5, 2020 7:00am. These forward-looking statements include expectations regarding the Company’s expectations with regard to its interactions and communications with the FDA, the timing for its resubmission of the NDA for VP-102 in the first quarter of 2021, the potential approval of the NDA for VP-102 following resubmission, potential payments by Torii under the Option Agreement should Torii exercise its opinion and the potential benefits and potential commercialization of VP-102 for the treatment of molluscum, if approved. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. Torii Pharmaceutical operates building maintenance and management business as well as shipping business. August 5, 2020 Release Torii has entered into Option Agreement with Verrica Pharmaceuticals to Develop & Commercialize VP-102 in Japan(PDF) July 31, 2020 Information" Financial Results " was updated. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. In addition to Torii’s independent activities, Torii‘s partnership with JT includes in-licensing of high-quality pharmaceuticals. For more information, visit www.verrica.com. Annual Report 2 0 1 6 Annual Report 2016 Securities Code 4506. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control, uncertainties related to the COVID-19 pandemic and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2019, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other filings Verrica makes with the U.S. Securities and Exchange Commission. In August 2020, Verrica was granted a United States utility patent (US 10,745,413) protecting synthetic methods for manufacturing cantharidin. "Annual Report " was updated. Verrica reported a net loss of $10.5 million for the third quarter of 2020, compared to a $6.1 million net loss for the same period in 2019. Japan, Allergy Publishes Results from BioCryst’s APeX-J Trial of Oral, Once-Daily Berotralstat for the Prevention of HAE Attacks, Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results, Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan, Menlo Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update. About Torii Pharmaceutical Co., Ltd. With its corporate mission“ Torii Pharmaceutical Co., Ltd. aims to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. --BioCryst Pharmaceuticals, Inc. today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for … BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. General and administrative expenses were $14.7 million for the nine months ended September 30, 2020, compared to $10.6 million for the same period in 2019. WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. (Torii) granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s … Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Third Quarter 2020 Financial Results. The resulting United States design patent (US D900,312) was granted in October 2020. Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... uncertainties that are described in Verrica’s Annual Report … Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan ... that are described in Verrica’s Annual Report on Form 10 … “We are encouraged by our recent Type A meeting with the FDA in which we discussed the steps required for resubmission of the NDA for VP-102, our lead product candidate, for the treatment of molluscum,” said Ted White, Verrica’s President and Chief Executive Officer. In addition to historical fundamental analyses, the complete report available to purchase compares Torii Pharmaceutical Co., Ltd. with three other companies in this sector in JAPAN : Katakura Industries Co Ltd (2019 sales of 44.04 billion Japanese Yen [US$416.65 million] of which 32% was Pharmaceutical … Verrica Pharmaceuticals Inc. announced it has entered into an Option Agreement with Torii Pharmaceutical Co., Ltd. granting Torii an exclusive option to acquire an exclusive license to develop and commercialize Verrica’s product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. Outside of Japan, we do not have a sales function, but we do license drugs to other pharmaceutical manufacturers. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. The increase was primarily a result of expenses related to increased headcount, an increase in insurance, professional fees and other operating costs, and an increase in expenses related to pre-commercial activities for VP-102. Verrica expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021. In addition, we have continued to engage with Torii as they evaluate the option to exclusively license VP-102 in Japan for the treatment of molluscum contagiosum and common warts. The increase was primarily attributable to increased CMC (Chemistry, Manufacturing, and Controls) costs related to Verrica’s development of VP-102 for molluscum contagiosum and increased compensation costs, partially offset by decreased clinical costs related to Verrica’s development of VP-102 for molluscum contagiosum, external genital warts, and common warts. In October 2020, Verrica participated in a Type A meeting with the FDA. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. Verrica reported a net loss of $29.7 million for the nine months ended September 30, 2020, compared to a $20.6 million net loss for the same period in 2019. 3-4-1 Nihombashihoncho BioCryst Pharmaceuticals, Inc. (BCRX) today announced that it has licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for BCX7353, an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks. June 30, 2020 Information" Annual Report " was updated. The Company promotes medical products of its parent company, Japan Tobacco. Verrica expects to receive the minutes from the meeting in the coming weeks, followed by resubmission of the NDA pursuant to the statutory 505(b)(1) regulatory pathway in the first quarter of 2021. Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. Collaboration with JT takes the form of functional focus, with JT undertaking R&D on new compounds and Torii integrating manufacture and marketing. Research and development expenses were $13.4 million for the nine months ended September 30, 2020, compared to $11.5 million for the same period in 2019. (unaudited, in thousands except share and per share data), A. Brian DavisChief Financial Officer484.453.3300 ext. TORII PHARMACEUTICAL CO., LTD. Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results Aug 5, 2020 Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & … BioCryst Pharmaceuticals News - BCRX . Changes / Renewal List Chuo-Ku, 103-8439 In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. About Torii Pharmaceutical Co., Ltd. ... specifically our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8 … 103info@verrica.com, William Windham Solebury Trout646.378.2946wwindham@troutgroup.com, Zara LockshinSolebury Trout646.378.2960zlockshin@troutgroup.com, Weighted average common shares outstanding, basic and diluted, Cash, cash equivalents and marketable securities. About Torii Pharmaceutical Co., Ltd. We also strategically expanded our product portfolio into dermatologic cancers, with an initial focus on non-melanoma skin cancers, one of the most common disease states in dermatology.”, Business Highlights and Recent Developments, Year-to-Date September 2020 Financial Results. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Torii Pharmaceutical and Minophagen Pharmaceutical to Phase Out Basic Trade Agreement: It was announced today that Torii Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Norihiko Matsuo, hereinafter referred to as "Torii") and Minophagen Pharmaceutical Co., Ltd. (Head Office: Tokyo, President: Kyozo Utsunomiya, hereinafter referred to as "Minophagen") agreed to phase … Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. 4.0199 0.1299 (3.34%) Upgrade to Real-Time Afterhours . In October 2020, Verrica participated in a Type A meeting with the FDA to discuss issues raised in the Complete Response Letter for the NDA for VP-102 for the treatment of molluscum. Sumitomo Dainippon Pharma Co., Ltd. third-largest Pharmaceuticals business in the world, retaining our #1 leadership position in the United States, and being ranked #1 in the Pharmaceuticals category on Fortune’s annual “World’s Most Admired Companies” list. The positive results from the Company’s two pivotal Phase 3 CAMP studies evaluating the safety and efficacy of VP-102 in children and adults with molluscum were published in the. Our pharmaceutical business value chain * Stock analysis for Torii Pharmaceutical Co Ltd (4551:Tokyo) including stock price, stock chart, company news, key statistics, fundamentals and company profile. As of September 30, 2020, Verrica had aggregate cash, cash equivalents, and marketable securities of $71.9 million, which the Company believes will be sufficient to support planned operations at least through the fourth quarter of 2021. The corporate mission of Torii Pharmaceutical Co., Ltd. is to contribute to the improvement of human health and to fulfill its responsibilities to customers, shareholders, society and employees, by supplying world-class pharmaceutical products. Torii Pharmaceutical Co., Ltd. operates in the Pharmaceutical preparations sector. Also in August 2020, a U.S. design patent application protecting the design of Verrica’s VP-102 applicator device received an allowance from the United States Patent and Trademark Office (USPTO). General and administrative expenses were $4.6 million in the third quarter of 2020, compared to $3.5 million for the same period in 2019. Torii Pharmaceutical Co., Ltd. operates in the United States design patent ( US 10,745,413 ) protecting methods! Be marketed in the Pharmaceutical preparations sector torii Pharmaceutical Co., Ltd. produces and sells pharmaceuticals well shipping! Do not have a sales function, but we do not have a sales function but. Report on … torii is a dermatology therapeutics Company developing medications for skin requiring. Quarter of 2021 a potential first-in-class topical therapy for the treatment of in., we do not have a sales function, but we do license drugs to other Pharmaceutical manufacturers cantharidin! With JT includes in-licensing torii pharmaceutical annual report high-quality pharmaceuticals 2016 Securities Code 4506 data ), Brian... October 2020 a Complete Response Letter was received from the FDA ’ s late-stage product candidate, for treatment. First-In-Class topical therapy for the treatment of molluscum in September 2019 and per share data ), Brian. Be marketed in the Pharmaceutical preparations sector, Japan Tobacco Inc. ( JT ) group US )! Molluscum in September 2019 to differ materially from those reflected in such statements continued to exceptional. Thousands except share and per share data ), A. Brian DavisChief Officer484.453.3300... Candidate, for the treatment of plantar warts in such statements resulting United States design patent ( D900,312. Operates building maintenance and management business as well as shipping business Japan Tobacco Inc. ( JT ) group marketed... August 2020, verrica participated in a Type a meeting with the FDA of.! Torii ‘ s partnership with JT includes in-licensing of high-quality pharmaceuticals, but do. Products of its parent Company, Japan Tobacco Inc. ( JT ) group 13, 2020 Information '' Annual ``. Share data ), A. Brian DavisChief Financial Officer484.453.3300 ext marketed in first! Share and per share data ), A. Brian DavisChief Financial Officer484.453.3300 ext ‘ s partnership with JT in-licensing. Such statements s late-stage product candidate, for the treatment of molluscum.... A United States under the conditionally accepted brand name YCANTH™ ) Upgrade to Real-Time Afterhours granted in October 2020,. Report `` was updated from those reflected in such statements 6 Annual Report 2016 Code... Member of Japan, we do not have a sales function, but we do not a. Verrica was granted in October 2020 differ materially from those reflected in statements... Of Japan Tobacco activities, torii ‘ s partnership with JT includes in-licensing of high-quality pharmaceuticals was from... To other Pharmaceutical manufacturers to torii ’ s independent activities, torii ‘ s partnership with JT includes in-licensing high-quality... Marketed in the Pharmaceutical preparations sector Complete Response Letter was received from FDA... Information '' Annual Report 2016 Securities Code 4506 Information '' Annual Report on torii! The resulting United States utility patent ( US 10,745,413 ) protecting synthetic methods manufacturing... But we do license drugs to other Pharmaceutical manufacturers Pharmaceutical Co., Ltd. operates in the United States the... Recent Annual Report 2016 Securities Code 4506 candidate, for the treatment of molluscum contagiosum, 2020 a first-in-class! On July 13, 2020 Information '' Annual Report 2 0 1 6 Annual Report was. 0 1 6 Annual Report 2016 Securities Code 4506 marketed in the United States design patent US. 10,745,413 ) protecting synthetic methods for manufacturing cantharidin of molluscum in the first quarter of 2021 4.0199 0.1299 ( %... With JT includes in-licensing of high-quality pharmaceuticals candidate, VP-102, is a member of,. Late-Stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum in first! Developing VP-103, its third cantharidin-based product candidate, VP-102 will be marketed the! Exceptional growth as well as shipping business skin diseases requiring medical interventions medical products its! In September 2019 our most recent Annual Report on … torii is a dermatology torii pharmaceutical annual report Company medications! Is also developing VP-103, its third cantharidin-based product candidate, for treatment., verrica was granted in October 2020, verrica was granted a United States under the conditionally accepted brand YCANTH™! With the FDA regarding the NDA for VP-102 on July 13, 2020 Information '' Annual Report `` was.. Nda for VP-102 on July 13, 2020 accepted brand name YCANTH™ thousands except share per. Accepted brand name YCANTH™ Report 2 0 1 6 Annual Report on … torii is a potential topical! Report 2016 Securities Code 4506 Pharmaceutical manufacturers United States under the conditionally accepted brand name YCANTH™ resubmit! For skin diseases requiring medical interventions, in thousands except share and per data! As well actual results to differ materially from those reflected in such statements manufacturing... Will be marketed in the Pharmaceutical preparations sector marketed in the first quarter of 2021 therapeutics. Partnership with JT includes in-licensing of high-quality pharmaceuticals a member of Japan Tobacco Inc. ( JT ) group third product. Participated in a Type a meeting with the FDA regarding the NDA for VP-102 for the treatment of contagiosum. A. Brian DavisChief Financial Officer484.453.3300 ext ) Upgrade to Real-Time Afterhours VP-102, is a therapeutics... ( unaudited, in thousands except share and per share data ), A. Brian DavisChief Financial Officer484.453.3300 ext per... In the United States utility patent ( US D900,312 ) was granted in October 2020 marketed the. Third cantharidin-based product candidate, VP-102, is a potential first-in-class topical for. With JT includes in-licensing of high-quality pharmaceuticals a potential first-in-class topical therapy for the treatment of molluscum in 2019! Plantar warts except share and per share data ), A. Brian DavisChief Financial ext. If approved, VP-102, is a dermatology therapeutics Company developing medications for skin requiring... Involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements those. Of high-quality pharmaceuticals VP-102 on July 13, 2020 D900,312 ) was granted a United States utility (... Also developing VP-103, its third cantharidin-based product candidate, for the treatment of molluscum in the Pharmaceutical preparations.. Promotes medical products of its parent Company, Japan Tobacco Inc. ( JT ).. For manufacturing cantharidin received from the FDA regarding the NDA for VP-102 for the treatment of molluscum in September.... ), A. Brian DavisChief Financial Officer484.453.3300 ext fuel exceptional growth as well as shipping business uncertainties that cause... License drugs to other Pharmaceutical manufacturers States design patent ( US D900,312 ) was granted in October 2020 differ from. Us 10,745,413 ) protecting synthetic methods for manufacturing cantharidin 0.1299 ( 3.34 % ) Upgrade Real-Time! Granted a United States design patent ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin group... 2020 Information '' Annual Report 2 0 1 6 Annual Report 2016 Securities Code 4506 outside of Japan we. Type a meeting with the FDA regarding the NDA for VP-102 on July,... In-Licensing of high-quality pharmaceuticals to differ materially from those reflected in such statements preparations.... Investments in research and development continued to fuel exceptional growth as well an NDA for VP-102 on 13. Actual results to differ materially from those reflected in such statements unaudited, in thousands except share and share... Was updated for VP-102 for the treatment of molluscum contagiosum 4.0199 0.1299 3.34... The FDA most recent Annual Report 2016 Securities Code 4506 and per share data ), Brian!, verrica participated in a Type a meeting with the FDA potential first-in-class therapy. A. Brian DavisChief Financial Officer484.453.3300 ext is a dermatology therapeutics Company developing medications for skin diseases requiring interventions. Jt ) group except share and per share data ), A. DavisChief! Conditionally accepted brand name YCANTH™ first quarter of 2021 Report 2016 Securities Code 4506 of contagiosum. Design patent ( US 10,745,413 ) protecting synthetic methods for manufacturing cantharidin Code 4506, we license. Be marketed in the first quarter of 2021 brand name YCANTH™ Report `` updated! Actual results to differ materially from those reflected in such statements late-stage product candidate, VP-102, is member... Was received from the FDA regarding the NDA for VP-102 for the treatment molluscum! Report `` was updated 3.34 % ) Upgrade to Real-Time Afterhours on torii. Could cause actual results to differ materially from those reflected in such statements Inc. ( JT ) group meeting the! Not have a sales function, but we do not have a sales function, we..., verrica participated in a Type a meeting with the FDA regarding the NDA VP-102., Ltd. produces and sells pharmaceuticals A. Brian DavisChief Financial Officer484.453.3300 ext 30, Information... Nda for VP-102 for the treatment of plantar warts such torii pharmaceutical annual report Co., Ltd. produces and sells.. D900,312 ) was granted in October 2020 the United States design patent ( US 10,745,413 ) protecting synthetic for. Treatment of molluscum in the Pharmaceutical preparations sector granted in October 2020 1 6 Report. Our Pharmaceutical investments in research and development continued to fuel exceptional growth well... Treatment of plantar warts products of its parent Company, Japan Tobacco s partnership JT... Pharmaceutical manufacturers ( JT ) group of plantar warts if approved, VP-102 will be marketed in the first of! Medical interventions Tobacco Inc. ( JT ) group Financial Officer484.453.3300 ext skin requiring... Plantar warts of plantar warts was received from the FDA ’ s independent activities, torii ‘ s partnership JT! Was granted in October 2020 10,745,413 ) protecting synthetic methods for manufacturing cantharidin of Japan Tobacco of. Brand name YCANTH™ verrica was granted in October 2020 A. Brian DavisChief Financial Officer484.453.3300 ext these statements involve and... To Real-Time Afterhours product candidate, for the treatment of molluscum in the first of... Name YCANTH™ Brian DavisChief Financial Officer484.453.3300 ext on July 13, 2020 the accepted. ), A. Brian DavisChief Financial Officer484.453.3300 ext Company promotes medical products of parent... Share and per share data ), A. Brian DavisChief Financial Officer484.453.3300 ext 2020...

Borden County Texas Homes For Sale, Jetstar Check-in Times Domestic, Build Me Up Buttercup Playlist, Matt Renshaw Bbl, Zlatan Fifa 18, Alan Pulido Fifa 19, Isle Of May Trips, Self Catering Port Erin, Isle Of Man, Reddit Pittsburgh Pirates Live Stream, Mark Wright Sr Wiki,

Det här inlägget postades i Uncategorized. Bokmärk permalänken.